Table 1.
Relationships between clinical-pathological characteristics and these three genes in patients with lung adenocarcinoma
| Variable | Total | EML4-ALK rearrangement | EGFR mutation | KRAS mutation | ||||||
|---|---|---|---|---|---|---|---|---|---|---|
| 131 | n | % | P-value | n | % | P-value | n | % | P-value | |
| Gender | 0.502 | 0.001 | 0.728 | |||||||
| Male | 74 | 4 | 5.41 | 26 | 35.14 | 4 | 5.41 | |||
| Female | 57 | 5 | 8.77 | 37 | 64.91 | 4 | 7.02 | |||
| Age | 0.687 | 1.000 | 0.658 | |||||||
| ≤65 | 105 | 8 | 7.61 | 51 | 48.57 | 6 | 5.71 | |||
| >65 | 26 | 1 | 3.84 | 12 | 46.15 | 2 | 7.69 | |||
| Smoking status | 0.077 | <0.001 | 0.728 | |||||||
| Never | 74 | 8 | 10.81 | 46 | 62.16 | 4 | 5.41 | |||
| Ever | 57 | 1 | 1.75 | 17 | 29.82 | 4 | 7.02 | |||
| Family history† | 1.000 | 0.215 | 1.000 | |||||||
| No | 112 | 8 | 7.14 | 51 | 45.54 | 7 | 6.25 | |||
| Yes | 19 | 1 | 5.26 | 12 | 63.16 | 1 | 5.26 | |||
| PTNM stage | 0.293 | 0.060 | 0.691 | |||||||
| IA | 29 | 3 | 10.34 | 13 | 44.83 | 1 | 3.45 | |||
| IB | 32 | 2 | 6.25 | 15 | 46.88 | 3 | 9.38 | |||
| IIA | 11 | 1 | 9.09 | 2 | 18.18 | 1 | 9.09 | |||
| IIB | 5 | 1 | 20.00 | 2 | 40.00 | 1 | 20.00 | |||
| IIIA | 38 | 1 | 2.63 | 21 | 55.26 | 2 | 5.26 | |||
| IIIB | 3 | 1 | 33.33 | 0 | 0.00 | 0 | 0.00 | |||
| IV | 13 | 0 | 0.00 | 10 | 76.92 | 0 | 0.00 | |||
†
Family history: whether the three generations of immediate family members of the patients had malignant tumor. EGFR, epidermal growth factor receptor; EML4-ALK, echinoderm microtubule-associated protein-like 4-anaplastic lymphoma kinase; KRAS, v-Ki-ras2 Kirsten rat sarcoma viral oncogene homolog; PTNM, pathological tumor node metastasis stage.